Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Tritschler

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Transplantation Proceedings|December 1, 1994
Tolerance induction by soluble CTLA4 in a mouse skin transplant modelM A Tepper, P S Linsley, D Tritschler, et al.
The Journal of Biological Chemistry|February 14, 1997
Differential expression and sequence-specific interaction of karyopherin alpha with nuclear localization sequencesS G Nadler, D Tritschler, O K Haffar, et al.
Journal of Pharmaceutical Sciences|March 1, 1996
A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in miceN R Srinivas, R S Weiner, W C Shyu, et al.
Tissue Antigens|October 1, 1996
Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigenM S Hayden, L S Grosmaire, N A Norris, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Transplantation Proceedings|December 1, 1994
Tolerance induction by soluble CTLA4 in a mouse skin transplant modelM A Tepper, P S Linsley, D Tritschler, et al.
The Journal of Biological Chemistry|February 14, 1997
Differential expression and sequence-specific interaction of karyopherin alpha with nuclear localization sequencesS G Nadler, D Tritschler, O K Haffar, et al.
Journal of Pharmaceutical Sciences|March 1, 1996
A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in miceN R Srinivas, R S Weiner, W C Shyu, et al.
Tissue Antigens|October 1, 1996
Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigenM S Hayden, L S Grosmaire, N A Norris, et al.
Pageof 1